While there are a number of contenders for dissing AI (and people who slavishly make it a part of their everyday lives), so ...

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...

Owing to Briumvi's solid launch, TG's balance sheet is in excellent condition. Despite new competition, Briumvi's five-year ...